- Home
- NGNE vs BACQ Comparison
NGNE vs BACQ Comparison
Compare NGNE & BACQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- BACQ
- Stock Information
- Founded
- NGNE 2003
- BACQ 2024
- Country
- NGNE United States
- BACQ United States
- Employees
- NGNE N/A
- BACQ N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- BACQ
- Sector
- NGNE Health Care
- BACQ
- Exchange
- NGNE Nasdaq
- BACQ NYSE
- Market Cap
- NGNE 213.2M
- BACQ 347.7M
- IPO Year
- NGNE N/A
- BACQ 2024
- Fundamental
- Price
- NGNE $21.94
- BACQ $10.29
- Analyst Decision
- NGNE Strong Buy
- BACQ
- Analyst Count
- NGNE 7
- BACQ 0
- Target Price
- NGNE $41.86
- BACQ N/A
- AVG Volume (30 Days)
- NGNE 222.5K
- BACQ 92.9K
- Earning Date
- NGNE 08-08-2025
- BACQ 01-01-0001
- Dividend Yield
- NGNE N/A
- BACQ N/A
- EPS Growth
- NGNE N/A
- BACQ N/A
- EPS
- NGNE N/A
- BACQ N/A
- Revenue
- NGNE $925,000.00
- BACQ N/A
- Revenue This Year
- NGNE N/A
- BACQ N/A
- Revenue Next Year
- NGNE N/A
- BACQ N/A
- P/E Ratio
- NGNE N/A
- BACQ $114.40
- Revenue Growth
- NGNE N/A
- BACQ N/A
- 52 Week Low
- NGNE $6.88
- BACQ $9.80
- 52 Week High
- NGNE $74.49
- BACQ $10.45
- Technical
- Relative Strength Index (RSI)
- NGNE 62.83
- BACQ N/A
- Support Level
- NGNE $19.01
- BACQ N/A
- Resistance Level
- NGNE $18.21
- BACQ N/A
- Average True Range (ATR)
- NGNE 1.65
- BACQ 0.00
- MACD
- NGNE 0.41
- BACQ 0.00
- Stochastic Oscillator
- NGNE 96.68
- BACQ 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About BACQ BLEICHROEDER ACQUISITION CORP. I
Bleichroeder Acquisition Corp I is a blank check company.